Previous 10 | Next 10 |
Live Youtube Broadcast with Expert Panelists on March 26, 2020 in MediWeb Studios BOSTON, MASSACHUSETTS, March 12, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by deliver...
Journal Article correlates different neurological pathologies with Brain Metabolic Score and examines a neurological case study BOSTON, MASSACHUSETTS, Feb. 28, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-...
Phoenix, Arizona--(Newsfile Corp. - February 12, 2020) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, David Platt, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on...
BXT-25 has the potential to treat late stage acute respiratory distress syndrome (ARDS) which is the leading cause of death in coronavirus patients. BOSTON, MASSACHUSETTS, Feb. 05, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company ...
Journal Article Evaluates Viability of Neuroprotectants as a functional Endpoint in Ischemic Stroke and Other Diseases BOSTON, MASSACHUSETTS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs ...
Phoenix, Arizona--(Newsfile Corp. - December 3, 2019) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, Dr. David Platt, joined Stock Day host Everett Jolly. To begin the interview, Platt shared som...
MDX Viewer provides essential data in critical care patients BOSTON, MASSACHUSETTS, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company focused on a pipeline of drugs designed to treat hypoxia, by delivering nanoscale oxygen carrie...
Phoenix, Arizona--(Newsfile Corp. - October 21, 2019) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, David Platt, joined Stock Day host Everett Jolly. Jolly began the interview by welcoming Plat...
Platform technology destined to measure and treat hypoxia BOSTON, MASSACHUSETTS, Oct. 16, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), is a developmental stage biotechnology company, focused on a pipeline of drugs designed to treat hypoxia, by delivering nanoscale oxygen c...
BOSTON, MASSACHUSETTS, Sept. 13, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company, focused on delivering a small molecule carrying oxygen to the brains of stroke victims, announced today that it has invited John Jensen and Dr. Patrick Huddie ...
News, Short Squeeze, Breakout and More Instantly...
Bioxytran Inc Company Name:
BIXT Stock Symbol:
OTCMKTS Market:
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...